Dylan Dupuis
Stock Analyst at Roth MKM
(2.68)
# 2,047
Out of 4,736 analysts
9
Total ratings
44.44%
Success rate
33.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dylan Dupuis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Reinstates: Buy | $7 | $2.10 | +233.33% | 2 | Dec 19, 2023 | |
| IVA Inventiva | Reiterates: Buy | $11 | $2.17 | +406.91% | 2 | Sep 21, 2023 | |
| TERN Terns Pharmaceuticals | Reiterates: Buy | $23 | $4.45 | +416.85% | 3 | Aug 8, 2023 | |
| VKTX Viking Therapeutics | Assumes: Buy | $32 | $32.87 | -2.65% | 1 | May 31, 2023 | |
| UBX Unity Biotechnology | Initiates: Buy | $10 | $1.79 | +458.66% | 1 | May 31, 2023 |
Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $7
Current: $2.10
Upside: +233.33%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $2.17
Upside: +406.91%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $4.45
Upside: +416.85%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $32.87
Upside: -2.65%
Unity Biotechnology
May 31, 2023
Initiates: Buy
Price Target: $10
Current: $1.79
Upside: +458.66%